

### **AMENDMENTS TO THE CLAIMS:**

Please cancel claims 75, 83-91 and 99-102. Please amend claims 67-74, 76-82 and 92-98 as shown in the following list of the claims:

1.- 66. (Canceled).

67. (Currently Amended) An isolated or recombinant antibody which immunospecifically binds to the amino acid sequence of ~~Figure 28~~ SEQ ID: NO 38.

68. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 67, wherein said antibody is a polyclonal antibody.

69. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 67, wherein said antibody is a monoclonal antibody.

70. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 67, wherein said antibody is a conjugated monoclonal antibody.

71. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 67, wherein said antibody is detectably labeled.

72. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 71, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

73. (Currently Amended) A composition for administration to patients comprising ~~an~~ the antibody ~~composition according to~~ of claim 67 together with a physiologically acceptable diluent or carrier.

74. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 73, which is adapted for intravenous administration.

75. (Canceled).

76. (Currently Amended) An isolated or recombinant antibody which immunospecifically binds to one or more of the extracellular domains, or portions ~~and/or analogs thereof~~ of the rchd523 amino acid sequence of ~~Figure 28~~ SEQ ID: NO 38.

77. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 76, wherein said antibody is a polyclonal antibody.

78. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 76, wherein said antibody is a monoclonal antibody.

79. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 76, wherein said antibody is detectably labeled.

80. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 79, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

81. (Currently Amended) A composition for administration to patients comprising ~~an~~ the antibody ~~composition according to~~ of claim 76 together with a physiologically acceptable diluent or carrier.

82. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 81, which is adapted for intravenous administration.

83.-91. (Canceled).

92. (Currently Amended) An isolated or recombinant antibody which immunospecifically binds to the gene product encoded by a polynucleotide up-regulated in endothelial cells under increased shear stress, wherein said polynucleotide hybridizes under highly stringent conditions to the complement of (a) the polypeptide coding region from nucleotide residue number 559 to 1683 of SEQ ID NO:6; or (b) the polypeptide coding

region of the cDNA contained in plasmid pFCHD523, as deposited with the Agricultural Research Service Culture Collection as Accession Number B-21458, wherein said highly stringent conditions comprise hybridization in 0.5M ~~NaHPO<sub>4</sub>~~ NaHPO<sub>4</sub>, 7% sodium dodecyl sulphate (SDS), 1 mM EDTA at 65°C, and washing in 0.1X SSC / 0.1% SDS at 68 °C.

93. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 92, wherein said antibody is a polyclonal antibody.

94. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 92, wherein said antibody is a monoclonal antibody.

95. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 92, wherein said antibody is detectably labeled.

96. (Currently Amended) ~~An~~ The antibody ~~composition according to~~ of claim 95, wherein said detectable label is selected from the group consisting of fluorescent labeling compounds, bioluminescent compounds and radioisotopes or any combination thereof.

97. (Currently Amended) A composition for administration to patients comprising ~~an~~ the antibody ~~composition according to~~ of claim 92 together with a physiologically acceptable diluent or carrier.

98. (Currently Amended) ~~A~~ The composition ~~according to~~ of claim 97, which is adapted for intravenous administration.

99.-102. (Canceled).